Order Your Cancer Test
ABOUT XING Cancer Tests
We are an Australian-owned and operated cancer pathology lab that uses genetic sequencing to inform doctors and patients about precision cancer treatment options.
Precision medicine offers cancer patients therapy options that are targeted specifically to their cancer. XING Genomic Services offers a range of cancer genetic tests for both newly diagnosed cancer patients and patients dealing with a recurrence of their disease.
The results analysed in our lab will determine whether the genetic alterations found in your cancer match genetic changes that are associated with known therapies that may have not been previously considered by your treating doctor. Performing genetic testing is a powerful diagnostic tool that may also give you clarification of your cancer type.
All clinically relevant genetic alterations and possible clinical trials will be reported in a clear and easy to read personalised XING Genomic Services report. The information surrounding your results will facilitate a discussion between you and your medical team.
Which test is right for you?
Every day your DNA is damaged by environmental toxins such as cigarette smoke, alcohol, chemicals, sunburn or damaged through random errors in normal cell growth. Homologous recombination repair deficiency (HRD) means that DNA repair genes are not functioning properly and cannot repair damaged DNA. This causes further errors in DNA to accumulate, leading to cancer. The genetic and epigenetic causes of HRD can be measured by DNA sequencing using the oncoRevealTM HRD and BRM tests.
By using the combined HRD and BRM assays, predictive biomarkers can be identified and these can inform treatment with oral poly (ADP-ribose) polymerase inhibitor (PARPi) drugs as well as eligibility for PARPi clinical trials.
This is a multi-gene test that analyses 19 genes involved in homologous recombination repair deficiency (HRD) and 8 genes that are diagnostically significant. This test is aimed at breast, ovarian, prostate, and pancreatic cancers.
In addition, epigenetic causes of HRD can be quantitatively interrogated by testing the BRCA1 and RAD51C gene promoters.
Genes covered include:
ATR, ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, RAD50, RAD51, RAD51C, RAD51D, FANCA, FANCC, FANCD2, FANCE, FANCF, and MRE11; hot spot regions of PALB2 and NBN; and other genes of diagnostic significance including ARID1A, BRAF, CTNNB1, KRAS, PIK3CA, PPP2R1A, PTEN, and TP53.
Cancerous tumours can be found across all organs in the body. Similarly, common cancer causing gene alterations can be found in all tumour types. Many of these “hotspot alterations” can be matched to a drug to treat the cancer they are causing.
The oncoRevealTM Solid Tumor Panel (STP) test is a multi-gene test that can identify hotspot alterations considered to be driving alterations in some solid tumours. It includes hotspots in 47 genes involved in colorectal, thyroid, non-small cell lung, and pancreatic cancers, as well as melanomas, gastro-intestinal stromal tumours (GIST), and gliomas.
This is a multi-gene test that analyses hotspot alterations considered to be driving mutations in solid tumours. It includes hotspots in 47 genes involved in colorectal, thyroid, non-small cell lung, and pancreatic cancers, as well as melanoma, gastro-intestinal stromal tumours (GIST), and gliomas.
Edit genes covered include:
AKT1, ALK, ARAF, BRAF, CDKN2A, CTNNB1, CYSLTR2, DDR2, EGFR, EIF1AX, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, H3-3A, H3C2, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MET, NRAS, NTRK1, PDGFRA, PIK3CA, PLCB4, POLD1, POLE, PTEN, PTPN11, RAC1, RAF1, RET, SF3B1, SMAD4, SRSF2, STK11, TERT promoter, TP53, and TSHR.
NATA ISO 15189 accredited
XING Genomics Services delivers array-based and customised massively parallel sequencing solutions to clients in industry and academia using the iScan, NextSeq550, and NovaSeq platforms.